Keigo Okada

FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia

Ayako Nogami, Gaku Oshikawa, Keigo Okada et al. · Oncotarget · 2015 · 64 citations · Full text

Medicine, Oncology, Pharmacology +16

FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and by Inhibiting Bad and BIM

Daisuke Watanabe, Ayako Nogami, Keigo Okada et al. · Cancers · 2019 · 49 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress

Hiroki Akiyama, Yoshihiro Umezawa, Shinya Ishida et al. · Cancer Letters · 2019 · 36 citations

Life Sciences, Cancer Biology, Molecular Biology +13

FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway

Keigo Okada, Ayako Nogami, Shinya Ishida et al. · Oncotarget · 2017 · 35 citations · Full text

Medicine, Oncology, Pharmacology +16

Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2

Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa et al. · Oncotarget · 2018 · 25 citations · Full text

Life Sciences, Oncology, Pharmacology +17